Bristol-Myers Squibb

Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
beta thalassemia
rare disease
drug development
Acceleron
Bristol-Myers Squibb
Bluebird Bio
Sangamo Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Syros Pharmaceuticals
Flag link:
A Big Month Ahead for the FDA and Bristol-Myers Squibb
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Flag link:
Five Prime Therapeutics’ pancreatic cancer combo with Opdivo a bust
Five Prime Therapeutics’ pancreatic cancer combo with Opdivo a bust
Fierce Biotech
Five Prime Therapeutics
cabiralizumab
Bristol-Myers Squibb
Opdivo
pancreatic cancer
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Opdivo delivers superior five-year survival results in renal cell carcinoma
Opdivo delivers superior five-year survival results in renal cell carcinoma
Pharmaceutical Business Review
Bristol-Myers Squibb
Opdivo
clinical trials
renal cell carcinoma
Flag link:
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Fierce Biotech
Bristol-Myers Squibb
FDA
lisocabtagene maraleucel
priority review
CAR-T
Flag link:
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
BioSpace
earnings
Bristol-Myers Squibb
AbbVie
Novo Nordisk
Merck
GSK
Seattle Genetics
Flag link:
Top Companies in Pharm Country Ranked by Revenue
Top Companies in Pharm Country Ranked by Revenue
BioSpace
Connecticut
New York
New Jersey
Pennsylvania
Rhode Island
Merck
Bristol-Myers Squibb
Regeneron
Ipsen
Ovid Therapeutics
Codagenix
Flag link:
How Bristol-Myers Squibb Trounced Wall Street's Q4 Estimates
How Bristol-Myers Squibb Trounced Wall Street's Q4 Estimates
Motley Fool
Bristol-Myers Squibb
earnings
Celgene
M&A
Flag link:
Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings
Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings
Yahoo/Zacks.com
Bristol-Myers Squibb
earnings
Flag link:
Bristol-Myers forms fibrotic disease biotech, bags buyout option
Bristol-Myers forms fibrotic disease biotech, bags buyout option
Fierce Biotech
Bristol-Myers Squibb
BioMotiv
Anteros Pharmaceuticals
fibrotic disease
Flag link:
Bristol-Myers Withdraws European Application for Lung Cancer Combo
Bristol-Myers Withdraws European Application for Lung Cancer Combo
Motley Fool
Bristol-Myers Squibb
Europe
Opdivo
Yervoy
non-small cell lung cancer
Flag link:
Big pharma backed away from brain drugs. Is a return in sight?
Big pharma backed away from brain drugs. Is a return in sight?
BioPharma Dive
Big Pharma
Neuroscience
AstraZeneca
Bristol-Myers Squibb
GSK
Pfizer
Amgen
Flag link:
Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches
Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
blood cancer
Flag link:
JPM Monday roundup: No deals, but drug-pricing startup causes the biggest noise
JPM Monday roundup: No deals, but drug-pricing startup causes the biggest noise
Fierce Biotech
JPMHC 2020
M&A
Gilead Sciences
Bristol-Myers Squibb
Flag link:
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
Fierce Pharma
M&A
JPMHC 2020
Bristol-Myers Squibb
Celgene
Giovanni Caforio
Flag link:
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
JPMHC 2020
Bristol-Myers Squibb
Vertex Pharmaceuticals
Biomarin
Regeneron
Biogen
Alexion
Gilead Sciences
Amgen
Flag link:
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
Flag link:
B-MS, Sanofi Claim Hawaii is Violating Their Free Speech in Plavix Suit
B-MS, Sanofi Claim Hawaii is Violating Their Free Speech in Plavix Suit
RAPS.org
freedom of speech
Bristol-Myers Squibb
Sanofi
Hawaii
Plavix
Flag link:
A big finish confirms 2019 as a takeover year to remember
A big finish confirms 2019 as a takeover year to remember
EP Vantage
M&A
AbbVie
Allergan
Astellas
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Flag link:

Pages